Merck Kgaa Dm 5 (MKGAF) 100.2000 $MKGAF
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Is Sigma-Aldrich (SIAL) a Sell After Its Buyout Proposition? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 11:50AM CST
Zacks Investment Research has downgraded Sigma-Aldrich (SIAL) to a Zacks Rank #4 (Sell).
ROC: 79.20 (+0.33), NL: 7.65 (+0.02), SIAL: 138.20 (+0.07)
Germany's Merck sticking with consumer healthcare business
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:35AM CST
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Merck Collaboration Rules Out AstraZeneca Acquisition--For Now
Anyoption - at Seeking Alpha - Fri Nov 21, 2:06PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 57.78 (-0.91), PFE: 34.64 (-0.23), BIOD: 1.38 (-0.14)
Merck KGaA Q3 Earnings Rise Y/Y, 2014 View Upgraded - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 1:20PM CST
Merck KGaA (MKGAF) reported third-quarter 2014 earnings of $1.53 per American Depositary Receipt (ADR), up 0.2% from the year-ago quarter.
LCI: 57.78 (-0.91), VRX: 167.00 (-0.50), ADHD: 6.92 (+0.73)
BI begins enrollment in Phase 3 CRC trial
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 8:08AM CDT
MGNX: 34.09 (+0.10), IMMU: 3.84 (unch), ONCY: 0.51 (+0.02), ARQL: 1.35 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Sigma-Aldrich Offers Ascentis Express 2.0 Micron UHPLC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 3:00PM CDT
Sigma-Aldrich (SIAL) has launched Ascentis Express 2.0 micron built on Fused-Core particle design.
SIAL: 138.20 (+0.07), TROX: 22.59 (+0.40), FSI: 1.17 (-0.01)
Sigma-Aldrich to Acquire Cell Marque to Bolster IHC Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 11:30AM CDT
Sigma-Aldrich Corporation (SIAL) announced that it has agreed acquire Cell Marque Corporation in order to strengthen its diagnostic health capabilities.
GSM: 15.60 (+0.06), SIAL: 138.20 (+0.07), FSI: 1.17 (-0.01)
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:24PM CDT
The FDA received paragraph IV certification notice pertaining to BioMarin's (BMRN) Kuvan.
ENDP: 84.01 (+1.12), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30)
Merck KGaA Records the Largest Acquisition in Their History at $17 Billion (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 8:00AM CDT
Merck KGaA (MKGAF) will acquire Sigma-Aldrich for $17 billion, or $140 per share in cash.
SIAL: 138.20 (+0.07)
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), RGDO: 1.17 (+0.02)
Merck KGaA Teams Up with Sutro for ADCs Targeting Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 6:00PM CDT
Merck KGaA's (MKGAF) signed a collaboration and license agreement with Sutro Biopharma to develop antibody drug conjugates (ADCs) targeting cancer cells.
LCI: 57.78 (-0.91), AVNR: 16.96 (unch), SGEN: 31.57 (+0.36)
Merck KGaA-Lupin Ink Deal, Focus on Emerging Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:14PM CDT
Merck KGaA (MKGAF) entered into a partnership with Lupin Ltd. with the aim of expanding Merck KGaA's General Medicine & Endocrinology franchise in emerging markets.
LCI: 57.78 (-0.91), AVNR: 16.96 (unch), ANAC: 40.76 (-0.07)
Merck KGaA Stops All Tecemotide Studies for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:42PM CDT
Merck KGaA (MKGAF) stops all studies on tecemotide as a monotherapy for non-small cell lung cancer (NSCLC) and focuses on developing other candidates.
LCI: 57.78 (-0.91), AVNR: 16.96 (unch), ANAC: 40.76 (-0.07)
Merck KGaA's Kuvan Effective in Under-4 Year Olds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:35PM CDT
Merck KGaA (MKGAF) announced that Kuvan showed statistically significant 26-week data from the phase IIIb SPARK study in children (<4 years) with phenylketonuria.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), BMRN: 100.76 (+1.98)
Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
AGN: 229.49 (+1.87), MNK: 115.01 (+2.51), ENDP: 84.01 (+1.12)
Merck KGaA, Precision Biologics to Develop Cancer Antibody - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Feb 04, 5:46PM CST
Merck KGaA's (MKGAF) Life Science business, Merck Millipore announced an agreement with Texas-based Precision Biologics, Inc. for providing upstream process development services to the company for the advancement of a preclinical monoclonal antibody, NEO-201.
BCRX: 10.06 (-0.09), SCMP: 15.32 (+0.04), BIOD: 1.38 (-0.14)
Is Sigma-Aldrich (SIAL) a Sell After Its Buyout Proposition? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 30, 11:50AM CST
Zacks Investment Research has downgraded Sigma-Aldrich (SIAL) to a Zacks Rank #4 (Sell).
ROC: 79.20 (+0.33), NL: 7.65 (+0.02), SIAL: 138.20 (+0.07)
Germany's Merck sticking with consumer healthcare business
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 9:35AM CST
Vargatef cleared in Europe for lung cancer
Seeking Alpha - at Seeking Alpha - Fri Nov 28, 8:23AM CST
HTBX: 5.83 (+0.22), BIB: 141.30 (+2.39), INCY: 75.94 (+0.28), PFE: 34.64 (-0.23), IBB: 323.46 (+3.04), DRGS: 56.69 (unch), BIND: 6.06 (+0.21), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), ONTY: 1.57 (unch), ECYT: 5.26 (-0.02), BIS: 39.67 (-0.75), CLVS: 68.79 (+0.71), AZN: 69.96 (+0.20), MRK: 58.81 (-0.07), ARIA: 7.35 (+0.45), IRY: 49.63 (+0.34), IXJ: 104.21 (+0.61), FPRX: 24.63 (+0.63)
Merck Collaboration Rules Out AstraZeneca Acquisition--For Now
Anyoption - at Seeking Alpha - Fri Nov 21, 2:06PM CST
PFE: 34.64 (-0.23), AZN: 69.96 (+0.20)
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Industry Outlook
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 12:00AM CST
Pharma Industry Outlook: M&A, Licensing Abound - Zacks Analyst Interviews
ACT: 285.37 (+3.71), QLTI: 4.15 (unch), VRX: 167.00 (-0.50), AGN: 229.49 (+1.87), SHPG: 239.82 (+6.11), AUXL: 36.47 (-0.06), ABBV: 58.05 (+1.00), SNY: 49.42 (+0.82), ABT: 46.09 (+0.87), ENDP: 84.01 (+1.12), AKRX: 47.28 (-0.25), PFE: 34.64 (-0.23), INCY: 75.94 (+0.28), SLXP: 152.35 (+3.17), MYL: 55.85 (+1.34), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), BMY: 60.04 (+0.56), ACHN: 10.89 (-0.20), MRK: 58.81 (-0.07), AZN: 69.96 (+0.20), ICPT: 209.12 (+7.12), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Merck KGaA Ties Up with Pfizer on Immuno-oncology Deal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 5:15PM CST
Merck KGaA (MKGAF) inked a deal with Pfizer to co-develop and co-commercialize MSB0010718C as a potential treatment for multiple types of tumor.
LCI: 57.78 (-0.91), PFE: 34.64 (-0.23), BIOD: 1.38 (-0.14)
Merck KGaA Q3 Earnings Rise Y/Y, 2014 View Upgraded - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 1:20PM CST
Merck KGaA (MKGAF) reported third-quarter 2014 earnings of $1.53 per American Depositary Receipt (ADR), up 0.2% from the year-ago quarter.
LCI: 57.78 (-0.91), VRX: 167.00 (-0.50), ADHD: 6.92 (+0.73)
BI begins enrollment in Phase 3 CRC trial
Seeking Alpha - at Seeking Alpha - Tue Oct 21, 8:08AM CDT
MGNX: 34.09 (+0.10), IMMU: 3.84 (unch), ONCY: 0.51 (+0.02), ARQL: 1.35 (+0.04), AMGN: 153.48 (+0.30), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GILD: 101.90 (+1.10), SNY: 49.42 (+0.82), REGN: 402.40 (+0.66)
Sigma-Aldrich Offers Ascentis Express 2.0 Micron UHPLC - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Oct 08, 3:00PM CDT
Sigma-Aldrich (SIAL) has launched Ascentis Express 2.0 micron built on Fused-Core particle design.
SIAL: 138.20 (+0.07), TROX: 22.59 (+0.40), FSI: 1.17 (-0.01)
Sigma-Aldrich to Acquire Cell Marque to Bolster IHC Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Oct 06, 11:30AM CDT
Sigma-Aldrich Corporation (SIAL) announced that it has agreed acquire Cell Marque Corporation in order to strengthen its diagnostic health capabilities.
GSM: 15.60 (+0.06), SIAL: 138.20 (+0.07), FSI: 1.17 (-0.01)
BioMarin (BMRN) Faces Threat of Genericization for Kuvan - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 5:24PM CDT
The FDA received paragraph IV certification notice pertaining to BioMarin's (BMRN) Kuvan.
ENDP: 84.01 (+1.12), BMRN: 100.76 (+1.98), AMGN: 153.48 (+0.30)
Merck KGaA Records the Largest Acquisition in Their History at $17 Billion (Revised) - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 23, 8:00AM CDT
Merck KGaA (MKGAF) will acquire Sigma-Aldrich for $17 billion, or $140 per share in cash.
SIAL: 138.20 (+0.07)
Is Merck KGaA on Track with its "Fit for 2018" Program? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 19, 1:50PM CDT
Merck KGaA (MKGAF) remains on track for its "Fit for 2018" program and discusses its plans regarding the immunology, oncology and immuno-oncology pipeline.
BIIB: 391.66 (-0.45), GILD: 101.90 (+1.10), RGDO: 1.17 (+0.02)
Merck KGaA Teams Up with Sutro for ADCs Targeting Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 6:00PM CDT
Merck KGaA's (MKGAF) signed a collaboration and license agreement with Sutro Biopharma to develop antibody drug conjugates (ADCs) targeting cancer cells.
LCI: 57.78 (-0.91), AVNR: 16.96 (unch), SGEN: 31.57 (+0.36)
Merck KGaA-Lupin Ink Deal, Focus on Emerging Markets - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 3:14PM CDT
Merck KGaA (MKGAF) entered into a partnership with Lupin Ltd. with the aim of expanding Merck KGaA's General Medicine & Endocrinology franchise in emerging markets.
LCI: 57.78 (-0.91), AVNR: 16.96 (unch), ANAC: 40.76 (-0.07)
Merck KGaA Stops All Tecemotide Studies for Lung Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 15, 2:42PM CDT
Merck KGaA (MKGAF) stops all studies on tecemotide as a monotherapy for non-small cell lung cancer (NSCLC) and focuses on developing other candidates.
LCI: 57.78 (-0.91), AVNR: 16.96 (unch), ANAC: 40.76 (-0.07)
Merck KGaA's Kuvan Effective in Under-4 Year Olds - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Sep 05, 4:35PM CDT
Merck KGaA (MKGAF) announced that Kuvan showed statistically significant 26-week data from the phase IIIb SPARK study in children (<4 years) with phenylketonuria.
LCI: 57.78 (-0.91), ENDP: 84.01 (+1.12), BMRN: 100.76 (+1.98)
Merck KGaA in Deal with S-TARget, Allergy Pipeline in Focus - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 03, 5:50PM CDT
Merck KGaA's (MKGAF) Allergopharma, strikes deal with S-TARget therapeutics for developing a new generation of therapies for allergies using S-TIR technology.
AGN: 229.49 (+1.87), MNK: 115.01 (+2.51), ENDP: 84.01 (+1.12)
